Theratechnologies Inc. (TSX:TH)

Market Cap	179.78M
Revenue (ttm)	127.96M
Net Income (ttm)	-5.35M
Shares Out	45.98M
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	17.57
Dividend	n/a
Ex-Dividend Date	n/a

Volume	153,582
Average Volume	271,723
Open	3.840
Previous Close	3.910
Day's Range	3.800 - 4.030
52-Week Range	1.590 - 4.330
Beta	1.50
RSI	70.71
Earnings Date	Apr 9, 2025

About Theratechnologies

Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its product pipeline includes tesamorelin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 103
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: TH

Financial Performance

In 2024, Theratechnologies's revenue was $85.87 million, an increase of 5.02% compared to the previous year's $81.76 million. Losses were -$8.31 million, -65.33% less than in 2023.

Financial numbers in USD